[ CAS No. 141699-59-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 141699-59-4 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	Inquiry	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]}	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]}	{[ item.pr_usastock ]}		{[ item.pr_chinastock ]}	{[ item.pr_remark ]}	Login		Inquiry

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 141699-59-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 141699-59-4 ]

SDS Specification

Alternatived Products of [ 141699-59-4 ]

Product Details of [ 141699-59-4 ]

CAS No. :	141699-59-4	MDL No. :	MFCD04116220
Formula :	C₁₁H₂₁NO₅S	Boiling Point :	No data available
Linear Structure Formula :	-	InChI Key :	WOEQSXAIPTXOPY-UHFFFAOYSA-N
M.W :	279.35	Pubchem ID :	4184869
Synonyms :

Calculated chemistry of [ 141699-59-4 ] Expand+

Physicochemical Properties

Num. heavy atoms :	18
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.91
Num. rotatable bonds :	5
Num. H-bond acceptors :	5.0
Num. H-bond donors :	0.0
Molar Refractivity :	71.45
TPSA :	81.29 ?2

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.23 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.72
Log Po/w (XLOGP3) :	1.09
Log Po/w (WLOGP) :	2.06
Log Po/w (MLOGP) :	0.93
Log Po/w (SILICOS-IT) :	0.0
Consensus Log Po/w :	1.36

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.93
Solubility :	3.29 mg/ml ; 0.0118 mol/l
Class :	Very soluble
Log S (Ali) :	-2.39
Solubility :	1.14 mg/ml ; 0.00408 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-1.32
Solubility :	13.2 mg/ml ; 0.0474 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	2.8

Safety of [ 141699-59-4 ]

Signal Word:	Warning	Class:
Precautionary Statements:	P261-P301+P312-P302+P352-P304+P340-P305+P351+P338	UN#:
Hazard Statements:	H302-H315-H319-H335	Packing Group:
GHS Pictogram:

Application In Synthesis of [ 141699-59-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 141699-59-4 ]
Downstream synthetic route of [ 141699-59-4 ]

[ 141699-59-4 ] Synthesis Path-Upstream 1~2

1
[ 142-08-5 ]
[ 141699-59-4 ]
[ 887928-35-0 ]

Reference： [1] Patent: WO2006/55951, 2006, A2, . Location in patent: Page/Page column 64
[2] Patent: WO2006/63113, 2006, A2, . Location in patent: Page/Page column 123

2
[ 141699-59-4 ]
[ 1201935-36-5 ]

Reference： [1] Patent: WO2015/25197, 2015, A1,

[ 141699-59-4 ] Synthesis Path-Downstream 1~12

1
[ 612501-52-7 ]
[ 141699-59-4 ]
[ 612501-81-2 ]

Yield	Reaction Conditions	Operation in experiment
95%		Step 2: Preparation OF TERT-BUTVL 4-R4- 3-CHLORO-2-FLUOROANILINO)-7-METHOXVQUINAZOLIN-6- YLOXVLPIPERIDINE-1-CARBOXYLATE; 4- (3-CHLORO-2-FLUOROANILINO)-6-HYDROXY-7-METHOXYQUINAZOLINE (116.7 g), tert-butyl 4-methylsulfonyloxypiperidine 1-carboxylate (153.1 g), potassium carbonate (75.7 g) and NMP (700 ml), were stirred at 100C to 105C, under nitrogen, for 24 hours. The mixture was cooled to 75C to 80C before water (1080 ml) was added whilst maintaining the temperature above 70C. The mixture was stirred at 70C to 75C for 90 minutes then cooled to 20C to 25C. The resulting solid was filtered, washed with water (2 x 175 ml), and then dried in the vacuum oven between 50C and 55C to give tert-butyl 4- [4- (3-CHLORO-2- FLUOROANILINO) -7-METHOXYQUINAZOLIN-6-YLOXY] PIPERIDINE-1-CARBOXYLATE ; (174.4 G; 95% YIELD); Melting point: 192-193. 5C ; NMR Spectrum: (DMSO d6) 1.40-1. 42 (d, 9H); 1.62-1. 72 (m, 2H); 1.99-2. 08 (m, 2H); 3.24-3. 33 (m, 2H); 3.65-7. 73 (m, 2H); 4.00 (s, 3H); 4.76 (m 1H) ; 7.28 (s; 1H); 7.37 (t, 3H); 7.56 (t, 1H) ; 7.63 (t, 1H); 8.01 (s, 1H); 8.72 (s 1H); Mass Spectrum: (M+H) + 503.
84%	With potassium carbonate; In ethanol; water; for 16.5h;Reflux;Product distribution / selectivity;	Step 1: 6-[(1-tert-Butoxycarbonyl)piperidin-4-yl]oxy}-4-(3-chloro-2-fluoroanilino)-7-methoxy quinazoline4-(3-Chloro-2-fluoroanilino)-6-hydroxy-7-methoxyquinazoline (prepared as described in Step 2 of Example A; 60.00 g, 0.1828 mol), tert-Butyl(4-methanesulfonyloxy)piperidine-1-carboxylate (88.04 g, 0.3107 mol) and potassium carbonate (30.31 g, 0.2193 mol) were suspended in ethanol (584 ml) and water (58 ml), and the mixture was heated to reflux with stirring. Heating was continued at reflux for 16.5 hours. The mixture was then cooled to 70 C. and water (234 ml) was added over 60 minutes.The batch was stirred at 65 C. for a further 2 hours to establish crystallisation. The slurry was cooled to 20 C. over 6 hours. The product was isolated by filtration. The filter cake was slurried with aqueous ethanol (ethanol 117 ml, water 58 ml) and then displacement washed with aqueous ethanol (ethanol 117 ml, water 58 ml). The filter cake was then slurried with water (175 ml) and then displacement washed with water (175 ml). The product was dried in vacuo at 40 C. to give the title compound (81.5 g, 84%); 1H NMR (500 MHz, DMSO-d6) delta ppm 1.42 (s, 9H) 1.60-1.70 (m, 2H) 1.96-2.04 (m, 2H) 3.23-3.30 (m, 2H) 3.65-3.75 (m, 2H) 3.95 (s, 3H) 4.68-4.75 (m, 1H) 7.24 (s, 1H) 7.29 (t, J=8.06 Hz, 1H) 7.49 (t, J=7.50 Hz, 1H) 7.54 (t, J=7.19 Hz, 1H) 7.88 (s, 1H) 8.39 (s, 1H) 9.57 (s, 1H); Mass Spectrum: 503.5, 505.5.
60%	With cesium fluoride; In N,N-dimethyl acetamide; at 85℃; for 12h;	To a solution of compound 7 (1.44 g, 4.51 mmol) in DMA (15 mL) was added compound 8 (378 mg, 1.35 mmol) and CsF (685 mg, 4.51 mmol). The reaction mixture was heated to 85 C and stirred. At intervals of 2 h, 4 h and 6 h, each time compound 8 (378 mg, 1.35 mmol) and CsF (685 mg, 4.51 mmol) were added. After the final addition,the reaction mixture was stirred at 85 C for further 6 h. The solvent was removed under vacuum and the residual was partitioned between CH2Cl2 and water. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The crude product was purified by column chromatography with MeOH/CH2Cl2 (1:25) to afford 9 (1.37 g, 60%) as a pale yellow solid, mp 200-201 C. 1H NMR (DMSO-d6): d 9.59 (s, 1H), 8.39 (s, 1H), 7.88 (s, 1H), 7.55-7.48 (m, 2H), 7.29 (t, J = 8.0 Hz, 1H), 7.24 (s, 1H), 4.71 (s, 1H), 3.95 (s, 3H), 3.71-3.69 (m, 2H), 3.29-3.26 (m, 2H), 2.01-1.99 (m, 2H), 1.68-1.62 (m, 2H), 1.42 (s, 9H). LC-MS (ESI, m/z): calcd for C25H29ClFN4O4 ([M+H]+) 503.2, found 503.1.

58%	With cesium fluoride; In N,N-dimethyl acetamide; at 85℃; for 18h;	4- (3-CHLORO-2-FLUOROANILINO)-6-HYDROXY-7-METHOXYQUINAZOLINE from Step 2 (1870 mg, 5.85 mmol) was dissolved in DMA (50 ml). tert-Butyl (4-methanesulfonyloxy) piperidine-1- carboxylate (prepared as in Chemical & Pharmaceutical Bulletin 2001,49 (7), 822-829; 490 mg, 1.76 mmol) and cesium fluoride (890 mg, 5.85 mmol) were added, and the mixture was heated to 85C with stirring. At intervals of 2 hours, 4 hours and 6 hours, tert-butyl 4- METHANESULFONYLOXYPIPERIDINE-1-CARBOXYLATE and cesium fluoride were added in the above quantities to the reaction mixture. Heating was continued at 85C for a further 6 hours after the final addition. The solvent was evaporated, and the residue was partitioned between DCM (150 ml) and H20 (150 ML). The aqueous layer was extracted with DCM (4x 100 ml), and the extractions combined with the DCM layer. The combined DCM fractions were dried over MGS04 and evaporated. The residue was purified by chromatography, eluting with 0 to 2.5% (7: 1 MEOH/CONCENTRATED aqueous NH4OH) in DCM. The appropriate fractions were combined and evaporated, giving the product as a light brown foam (2.40 g, 58%, allowing for 2.3 equivalents of residual DMA).'H NMR : 1.40 (s, 9H), 1.60-1. 65 (m, 2H), 1.95-2. 00 (m, 2H), 3.20-3. 25 (m, 2H), 3.65-3. 70 (m, 2H), 3.92 (s, 3H), 4.68 (m, 1H), 7.21 (s, 1H), 7.27 (dd, 1H), 7.47 (ddd, 1H), 7.51 (dd, 1H), 7.85 (s, 1H), 8.36 (s, 1H), 9.53 (s, 1H) ; Mass Spectrum: 503.5, 505.5.
58%	With cesium fluoride; In N,N-dimethyl acetamide; at 85℃; for 18h;	4- (3-CHLORO-2-FLUOROANILINO)-6-HYDROXY-7-METHOXYQUINAZOLINE from Step 2 (1870 mg, 5.85 mmol) was dissolved in DMA (50 ml). tert-Butyl (4-methanesulfonyloxy) PIPERIDINE-1-CARBOXYLATE (prepared as in Chemical & Pharmaceutical Bulletin 2001,49 (7), 822-829; 490 mg, 1.76 mmol) and cesium fluoride (890 mg, 5.85 mmol) were added, and the mixture was heated to 85C with stirring. At intervals of 2 hours, 4 hours and 6 hours, tert-butyl 4-METHANESULFONYLOXYPIPERIDINE-1-CARBOXYLATE and cesium fluoride were added in the above quantities to the reaction mixture. Heating was continued at 85C for a further 6 hours after the final addition. The solvent was evaporated, and the residue was partitioned between DCM (150 ml) and H20 (150 ml). The aqueous layer was extracted with DCM (4x 100 ml), and the extractions combined with the DCM layer. The combined DCM fractions were dried over MGS04 and evaporated. The residue was purified by chromatography, eluting with 0 to 2.5% (7: 1 MEOH/CONCENTRATED aqueous NH40H) in DCM. The appropriate fractions were combined and evaporated, giving the product as a light brown foam (2.40 g, 58%, allowing for 2.3 equivalents of residual DMA); HNMR : 1.40 (s, 9H), 1.60-1. 65 (m, 2H), 1.95-2. 00 (m, 2H), 3.20-3. 25 (m, 2H), 3.65-3. 70 (m, 2H), 3.92 (s, 3H), 4.68 (m, 1H), 7.21 (s, 1H), 7.27 (dd, 1H), 7.47 (ddd, 1H), 7.51 (dd, 1H), 7.85 (s, 1H), 8.36 (s, 1H), 9.53 (s, 1H) ; Mass Spectrum: 503.5, 505.5.
58%	With cesium fluoride; In N,N-dimethyl acetamide; at 85℃; for 12h;	Reference Example 3; 6-[(1-tert-Butoxycarbonyl) piperidin-4-yl] oxy}-4-(3-chloro-2-fluoroanilino)-7- methoxyquinazoline; 4- (3-Chloro-2-fluoroanilino)-6-hydroxy-7-methoxyquinazoline (Reference Example 2,1870 mg, 5.85 mmol) was dissolved in DMA (50 ml). tert-Butyl (4- methanesulfonyloxy) piperidine-l-carboxylate (prepared as in Chemical & Pharmaceutical Bulletin 2001,49 (7), 822-829; 490 mg, 1.76 mmol) and cesium fluoride (890 mg, 5.85 mmol) were added, and the mixture was heated to 85C with stirring. At intervals of 2 hours, 4 hours and 6 hours, tert-butyl 4-methanesulfonyloxypiperidine-1-carboxylate and cesium fluoride were added in the above quantities to the reaction mixture. Heating was continued at 85C for a further 6 hours after the final addition. The solvent was evaporated, and the residue was partitioned between DCM (150 ml) and H20 (150 ml). The aqueous layer was extracted with DCM (4x 100 ml), and the extractions combined with the DCM layer. The combined DCM fractions were dried over MgS04 and evaporated. The residue was purified by chromatography, eluting with 0 to 2.5% (7: 1 MeOH/concentrated aqueous NH40H) in DCM. The appropriate fractions were combined and evaporated, giving the product as a light brown foam (2.40 g, 58%, allowing for 2.3 equivalents of residual DMA) ; 1H NMR : 1.40 (s, 9H), 1.60-1. 65 (m, 2H), 1.95-2. 00 (m, 2H), 3.20-3. 25 (m, 2H), 3.65-3. 70 (m, 2H), 3.92 (s, 3H), 4. 68 (m, 1H), 7.21 (s, 1H), 7.27 (dd, 1H), 7.47 (ddd, 1H), 7.51 (dd, 1H), 7.85 (s, 1H), 8.36 (s, 1H), 9.53 (s, 1H) ; Mass Spectrum : 503.5, 505.5

Reference： [1]Patent: WO2005/12290,2005,A1 .Location in patent: Page/Page column 41
[2]Patent: US2009/286982,2009,A1 .Location in patent: Page/Page column 15
[3]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 4455 - 4459
[4]Patent: WO2005/28470,2005,A1 .Location in patent: Page/Page column 54-55
[5]Patent: WO2005/28469,2005,A1 .Location in patent: Page/Page column 59
[6]Patent: WO2003/82831,2003,A1 .Location in patent: Page/Page column 162
[7]ACS Medicinal Chemistry Letters,2013,vol. 4,p. 742 - 746
[8]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 4908 - 4912

2
[ 2075-45-8 ]
[ 141699-59-4 ]
[ 877399-50-3 ]

Yield	Reaction Conditions	Operation in experiment
77%	With 1-methyl-pyrrolidin-2-one; caesium carbonate; at 80℃; for 12h;Large scale;	2.08 kg of cesium carbonate,0.78 kg of 4-bromopyrazole was dissolved in 4 liters of N-methylpyrrolidone,Heated to 80 degrees,A 5 liter solution of N-methylpyrrolidone was added to 1.8 kg of compound (CZT-7)Reaction for 12 hours.Cooled to room temperature,Add 50 litersMethyl tert-butyl etherwith50 liters of water,Stir for 1 hour.After dispensing,The organic phase was washed with 20 liters of * 4 water and dried 50percentLiter of hexane and stirred at room temperature for 2 hours. Filtered and dried to give 1.35 kg of compound (CZT-8) in a yield of 77percent
58%		B. To a cold solution (0 °C) of 4-bromo-lH-pyrazole (14.9 g, 0.10 mol) in 80 mL of dichloromethane was added sodium hydride (8.13 g, 0.20 mol) portion wise. The mixture was stirred at 0 °C for 1 hour, followed by the addition of a solution of tert-butyl 4-((methylsulfonyl)oxy)piperidine-l-carboxylate (34.0 g, 0.12 mol) in 30 mL of N,N-dimethylformamide. The resulting mixture was heated at 110 °C overnight. Purification by column chromatography afforded tert-butyl 4-(4-bromo-lH- pyrazol-l-yl)piperidine-l-carboxylate as a yellow oil in 58percent yield (19.5 g). 1H NMR (400 MHz, CDC13) delta 7.48 (s, 1H), 7.44 (s 1H), 4.35-4.20 (m, 3H), 2.95-2.85 (m, 2H), 2.15-2.05 (m, 2H), 1.92-1.81 (m, 2H), 1.48 (s, 9H).
45%		To a stirred solution of 4-bromo-pyrazole (10.44 g, 71.03 mmol) in anhydrous DMF (96 mL), cooled to 0° C., was slowly added NaH (60percent in mineral oil) (3.13 g, 78.133 mmol). The solution was stirred for 1 hour at 0° C. 4-Methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester (19.82 g, 71.03 mmol) was added slowly and the reaction was heated to 100° C. overnight or until consumption of the pyrazole by NMR. The reaction was cooled to room temperature and water added (20 mL) followed by extraction with EtOAc. The combined extracts were washed with saturated aqueous NaCl (4*20 mL), dried with Na2SO4 and concentrated to afford 4-(4-bromo-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester as an orange oil. The oil was purified using silica gel chromatography eluding with 10percent EtOAc/hexanes to 25percent EtOAc/hexanes to provide 4-(4-bromo-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester as a white solid (10.55 g, 45percent yield) with a Rf=0.4 (25percent EtOAc/hexanes, using iodine as the stain). 1H NMR (CDCl3, 400 MHz) delta 7.46 (s, 1H), 7.43 (s, 1H), 4.23 (m, 3H), 2.88 (m, 2H), 2.10 (m, 2H), 1.88 (m, 2H), 1.47 (s, 9H).

45%		To a stirred solution of 4-bromo-pyrazole (10.44 g, 71.03 mmol) in anhydrous DMF (96 mL), cooled to 0°C, was slowly added NaH (60percent in mineral oil) (3.13 g, 78.133 mmol). The solution was stirred for 1 hour at 0°C. 4-Methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester (19.82 g , 71.03 mmol) was added slowly and the reaction was heated to 100°C overnight or until consumption of the pyrazole by NMR. The reaction was cooled to room temperature and water added (20 mL) followed by extraction with EtOAc. The combined extracts were washed with saturated aqueous NaCI (4 x 20 mL), dried with Na2SO4 and concentrated to afford 4-(4-bromo-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester as an orange oil. The oil was purified using silica gel chromatography eluting with 10percent EtOAc/hexanes to 25percent EtOAc/hexanes to provide 4-(4-bromo-pyrazol-1-yl)-piperidine-1-carboxylic acid tert-butyl ester as a white solid (10.55 g, 45percent yield) with a R^= 0.4 (25percent EtOAc/hexanes, using iodine as the stain). 1H NMR (CDCI3, 400 MHz) 8 7.46 (s, 1H), 7.43 (s, 1H), 4.23 (m, 3H), 2.88 (m, 2H), 2.10 (m, 2H), 1.88(m, 2H), 1.47(s, 9H).
		NaH (60percent in mineral oil, 1.36 g, 34 mmol) is added portionwise to a stirred solution of 4- bromopyrazole (4.58 g, 30.9 mmol) in DMF (20 ml). The resulting mixture is stirred for 1h at O0C and 4-Methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester (as obtained in preparation 61 , 8.62 g, 30.9 mmol) is added. The resulting pale suspension is heated at 1000C for 1h. The reaction is quenched with water and extracted with EtOAc several times. The combined organic layers are washed with brine, dried over Na2SO4, filtered and the filtrate is concentrated in vacuo. The residue is purified by chromatography on a 120 g silica gel column on a Combiflash Companion.(TM). (Isco Inc.) apparatus ( gradient hexanes: TBDME from 1 :0 => 0:1) to afford the title compound as a colorless solid, Rt = 1.213 min (Acquity UPLC BEH C18, 2.1x50mm, 1.7 micron, detection 215nM, 0.1 min 2percent CH3CN in H2O , 2percent to 100percent CH3CN in H2O in 1.5min, 0.4 min 100percent CH3CN + 0.1 percent TFA, flow rate 1.0ml/min); MS: 330 (M+1, 79Br)+.
		As shown in step 3-ii of Scheme 3, to a solution of 4-bromopyrazole (4.68 g, 31.83 mmol) in DMF (300 mL) at 00C was added sodium hydride (60percent on mineral oil, 1.27 g, 31.83 mmol). The solution was stirred at 00C for one hour, at which point a solution of Compound 1013 (9.78 g, 31.83 mmol) in DMF (50 mL) was added dropwise. The reaction mixture was stirred at room temperature for 1 hour and then refluxed for 16 hours. Disappearance of both starting materials was observed by TLC (1 : 1 EtOAc/hexanes). The reaction was cooled to room temperature, quenched by the addition of brine (300 mL), and extracted with ethyl acetate (3 x 200 mL). The combined organics were washed with 1percent aqueous LiCl (3 x 200 mL), dried over sodium sulfate, and concentrated under reduced pressure. The resulting crude bromide was purified by silica gel chromatography (0 - 25percent EtOAc/hexanes) to give Compound 1014.
	With sodium hydride; In N,N-dimethyl-formamide; mineral oil; at 80℃; for 12h;	c) tert-Butyl 4-(4-bromo- 1 H-pyrazol- 1 -yl)piperidine- 1 -carboxylateTo a cooled solution of the compound of Intermediate Example 5(b) (6.7 g, 23.9 mmol) in DMF (50 ml) was added NaH (2.8 g, 1 19 mmol, 5 eq.) and 4-bromo-lH-pyra- zole (2.8 g, 19.1 mmol, 0.8 eq.) and stirred at 80 °C for 12 h. The mixture was quenched and extracted with ethyl acetate (3 chi 100 ml). The combined organic layer was washed with water, brine and dried over sodium sulphate. The solvent was distilled off to afford the crude product (8.0 g).
		General procedure: To an ice-cooled solution of 4-bromo-1H-pyrazole (1.19 g, 8.07 mmol) in 10 mL of DMF was added portionwise sodium hydride (355 mg, 8.88 mmol, 60percent in oil). The resulting mixture was stirred for additional 1 h. Then to the mixture was added oxan-4-yl methanesulfonate (1.60 g, 8.88 mmol), which was prepared in a similar manner as described for 12. The resulting mixture was gradually heated to 100 °C and stirred for 10 h. After cooled to room temperature, the reaction was quenched with water. The mixture was extracted with EA. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under vacuum. The crude product was purified by silica gel column chromatography (EA/PE, 1:6) to afford 26a as a white solid in 61percent yield.
	With sodium hydride; In N,N-dimethyl-formamide; at 80℃; for 12h;	To a cooled solution of the compound of Intermediate Example 5(b) (6.7 g, 23.9 mmol) in DMF (50 ml) was added NaH (2.8 g, 119 mmol, 5 eq.) and 4-bromo-1H-pyrazole (2.8 g, 19.1 mmol, 0.8 eq.) and stirred at 80° C. for 12 h. The mixture was quenched and extracted with ethyl acetate (3*100 ml). The combined organic layer was washed with water, brine and dried over sodium sulphate. The solvent was distilled off to afford the crude product (8.0 g).
	With sodium hydride; In N,N-dimethyl-formamide; at 20 - 110℃;Inert atmosphere;	Sodium hydride (400 mg, 60percent dispersion, 10 mmol) was added to a stirred solution of the bromopyrazole (1.47g, lOmmol) and 4-Methanesulfonyloxy-pipehdine-1-carboxylic acid tert-butyl ester (2.4 g, 8.6 mmol) in dry DMF (10 ml) at room temperature. After gas evolution had ceased, the reaction was stirred and heated at 110 0C under N2 for 4 h. The reaction mixture was allowed to cool to room temperature and stand at for 18 h before being partitioned between EtOAc and H2O. The organic layer was separated, washed with water H2O (x2), brine (x1 ), then dried (Na2SO4), filtered and the solvent removed in vacuo.The residue was purified using silica column chromatography running a 10-25percentEtOAc/petrol gradient to give a colourless oil (1.7 g, 5.15 mmol). 1 H NMR (400 MHz,CDCI3): 7.48 (1 H, s), 7.45 (1 H, s), 4.45-4.07 (3H, m), 2.90 (2H, t), 2.12 (2H, d), 1.97-1.79(2H, m), 1.50 (9H, s).

Reference： [1]Patent: CN106317024,2017,A .Location in patent: Paragraph 0060; 0061
[2]Journal of Medicinal Chemistry,2011,vol. 54,p. 4092 - 4108
[3]Patent: WO2015/81257,2015,A2 .Location in patent: Page/Page column 81
[4]Tetrahedron Letters,2014,vol. 55,p. 1528 - 1531
[5]Patent: US2006/46991,2006,A1 .Location in patent: Page/Page column 64-65
[6]Patent: WO2006/21881,2006,A2 .Location in patent: Page/Page column 74; 75
[7]Patent: WO2008/148867,2008,A2 .Location in patent: Page/Page column 51-52
[8]Patent: WO2010/48131,2010,A1 .Location in patent: Page/Page column 54
[9]Patent: WO2013/53983,2013,A1 .Location in patent: Page/Page column 31
[10]Bioorganic and Medicinal Chemistry,2013,vol. 21,p. 6804 - 6820
[11]Patent: US2015/11548,2015,A1 .Location in patent: Paragraph 0136
[12]Bioorganic Chemistry,2016,vol. 65,p. 146 - 158
[13]Patent: WO2009/150240,2009,A1 .Location in patent: Page/Page column 119

3
[ 4214-79-3 ]
[ 141699-59-4 ]
[ 442199-12-4 ]

Yield	Reaction Conditions	Operation in experiment
65%	With potassium carbonate; In N,N-dimethyl-formamide; at 20 - 75℃;	t-Butyl 4-(methanesulfonyloxy)piperidine-1-carboxylate (3.02 g, 10.8 mmol) and potassium carbonate (2.35 g, 17.0 mmol) were added to a N,N-dimethylformamide solution (77 ml) of <strong>[4214-79-3]5-chloro-2-hydroxypyridine</strong> (1.00 g, 7.72 mmol), at room temperature, and stirring was carried out at 75°C overnight. After the reaction solution was cooled to room temperature, water was added to the residue resulting from concentration, followed by extraction with methylene chloride. The resulting organic layer was dried over anhydrous sodium sulfate, and the residue resulting from concentration was purified by silica gel column chromatography to afford t-butyl 4-[(5-chloropyridin-2-yl)oxy]piperidine-1-carboxylate (1.57 g, yield 65percent) as a colorless oil. 1H-NMR (CDCl3, 400 MHz) delta: 8.06 (1H, d, J=2.7 Hz), 7.51 (1H, dd, J=8.8 Hz, 2.7 Hz), 6.67 (1H, d, J=8.8 Hz), 5.18-5.13 (1H, m), 3.79-3.73 (2H, m), 3.31-3.24 (2H, m), 1.99-1.93 (2H, m), 1.74-1.66 (2H, m), 1.47 (9H, s) .
32%	With potassium carbonate; In N,N-dimethyl-formamide; at 75℃;Sealed tube;	Potassium carbonate (0.352 g, 2.55 mmol) was added to a solution of tert-butyl 4-(methylsulfonyloxy)piperidine-1-carboxylate from step (i) (0.453 g, 1.621 mmol) and <strong>[4214-79-3]5-chloropyridin-2-ol</strong> (0.15 g, 1.158 mmol) in N,N-dimethylformamide (10 ml) in a sealed tube. The reaction was stirred at 75° C. overnight. The reaction was quenched with water and extracted with DCM three times. The combined organics were washed with water, dried (phase separator) and concentrated. The crude product was freeze-dried to remove the remaining DMF. The crude product was purified by 10 g KP-silica Biotage SNAP cartridge eluted with 0-50percent ethyl acetate/petrol to give tert-butyl 4-(5-chloropyridin-2-yloxy)piperidine-1-carboxylate (0.116 g, 0.371 mmol, 32.0percent yield). [0608] 1H NMR (400 MHz, Dichloromethane-d2) delta ppm 1.48 (s, 9H) 1.64-1.81 (m, 2H) 1.90-2.03 (m, 2H) 3.19-3.35 (m, 2H) 3.70-3.85 (m, 2H) 5.13-5.25 (m, 1H) 6.73 (s, 1H) 7.52-7.62 (m, 1H) 8.05-8.14 (m, 1H) [0609] MS ES+: 257
0.116 g	With potassium carbonate; In N,N-dimethyl-formamide; at 75℃;Sealed tube;	Step (ii): Potassium carbonate (0.352 g, 2.55 mmol) was added to a solution of tert-butyl 4- (methylsulfonyloxy)piperidine-l-carboxylate from step (i) (0.453 g, 1.621 mmol) and <strong>[4214-79-3]5-chloropyridin-2-ol</strong> (0.15 g, 1.158 mmol) in N,N-dimethylformamide (10 ml) in a sealed tube. The reaction was stirred at 75°C overnight. The reaction was quenched with water and extracted with DCM three times. The combined organics were washed with water, dried (phase separator) and concentrated. The crude product was freeze-dried to remove the remaining DMF. The crude product was purified by 10 g KP-silica Biotage SNAP cartridge eluted with 0-50percent ethyl acetate / petrol to give tert-butyl 4-(5-chloropyridin-2- yloxy)piperidine-l-carboxylate (0.116 g, 0.371 mmol, 32.0 percent yield). H NMR (400 MHz, Dichloromethane-i) delta ppm 1.48 (s, 9 H) 1.64 - 1.81 (m, 2 H) 1.90 - 2.03 (m, 2 H) 3.19 - 3.35 (m, 2 H) 3.70 - 3.85 (m, 2 H) 5.13 - 5.25 (m, 1 H) 6.73 (s, 1 H) 7.52 - 7.62 (m, 1 H) 8.05 - 8.14 (m, 1 H) MS ES+: 257

Reference： [1]Patent: EP2258697,2010,A1 .Location in patent: Page/Page column 48
[2]Patent: US2013/324576,2013,A1 .Location in patent: Paragraph 0606; 0607; 0608; 0609
[3]Patent: WO2013/179024,2013,A1 .Location in patent: Page/Page column 54

4
[ 5932-27-4 ]
[ 141699-59-4 ]
[ 1421065-44-2 ]

Yield	Reaction Conditions	Operation in experiment
56.5%	With potassium carbonate; In N,N-dimethyl-formamide; at 70℃; for 12h;	Example 14A2 4-(3-Ethoxycarbonyl-pyrazol- l-yl)-piperidine-l-carboxylic acid tert-butyl ester A mixture of Example 14A1 (1 g, 3.55 mmol), Example 4A (0.498 g, 3.55 mmol) and K2CO3 (1.47 g, 10.67 mmol) in DMF (20 mL) was heated at 70 °C for 12 hours. TLC (Petroleum ether: EtOAc = 4: 1) indicated that the reaction was completed. The reaction mixture was filtered and the filtrate was concentrated in vacuum and the residue was purified by chromatography on silica to give Example 14A2 (0.65 g, 56.5 percent) as a colorless solid.

Reference： [1]Patent: WO2013/10453,2013,A1 .Location in patent: Page/Page column 106-107

5
[ 5932-27-4 ]
[ 141699-59-4 ]
[ 1421065-45-3 ]

Reference： [1]Patent: WO2013/10453,2013,A1

6
[ 141699-59-4 ]
[ 224779-27-5 ]

Reference： [1]Patent: WO2013/138210,2013,A1

7
[ 1776-37-0 ]
[ 141699-59-4 ]
[ 1469326-84-8 ]

Yield	Reaction Conditions	Operation in experiment
1.04 g		To a solution of <strong>[1776-37-0]5-methylindazole</strong> (901 mg) in DMF (10 mL) was added sodium hydride (327 mg) at 0° C., and the mixture was stirred with heating at 40° C. for 30 minutes. To the reaction solution was added tert-butyl 4-(methylsulfonyloxy)piperidine-1-carboxylate (2.28 g), and the mixture was stirred with heating at 90° C. for 19 hours. Then, the mixture was partitioned between ethyl acetate and water, and the organic layer was washed with brine and dried over Na2SO4. The residue was purified by silica gel column chromatography (ethyl acetate:hexane=2:5 as the eluting solvent) to give Compound Q1 (1.04 g). [0225] 1H-NMR (400 MHz, CDCl3): 1.47 (9H, s), 2.00 (2H, m), 2.21 (2H, m), 2.43 (3H, s), 2.93 (2H, br), 4.28 (2H, br), 4.50 (1H, m), 7.19 (1H, d, J=8.0 Hz), 7.32 (1H, d, J=8.0 Hz), 7.48 (1H, s), 7.89 (1H, s)
1.04 g		in DMF solution of 5-methyl-indazole (901mg) (10mL) at 0 It was added sodium hydride (327 mg), heatedand stirred for 30 minutes at 40 ° C..?Thereafter,by adding to the reaction solution tert- butyl 4- (methylsulfonyloxy)piperidine-1-carboxylate (2.28 g) for 19 hours under heating and stirred at 90° C..?After completion of the reaction, ethyl acetate - toseparatory extraction with water, after which the resulting organic layer waswashed with saturated brine, and dried over sodium sulfate.?The resultingresidue was purified by silica gel column chromatography (elution solvent;ethyl acetate: hexane = 2: 5) to give compound Q1 (1.04g) purified by

Reference： [1]Patent: US2014/121243,2014,A1 .Location in patent: Paragraph 0224; 0225
[2]Patent: JP2015/96495,2015,A .Location in patent: Paragraph 0118

8
[ 19230-71-8 ]
[ 141699-59-4 ]
tert-butyl 4-(4-methyl-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate [ No CAS ]
tert-butyl 4-(4-methyl-1H-1,2,3-triazol-1-yl)-piperidine-1-carboxylate [ No CAS ]
tert-butyl 4-(5-methyl-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		4-Methyl-iH-i,2,3-triazole (357 mg, 4.30 mmol) was placed in a flask with dry DMF (5 mL). Sodium hydride (186 mg, 4.65 mmol) was added and the reaction mixture was stirred atroom temperature for 15 minutes. tert-Butyl 4-((methylsulfonyl)oxy)piperidine- 1 -carboxylate (step 1) (1.00 g, 3.58 mmol) was added and the reaction mixture was stirred at 100C for4 hours. The resulting mixture was partitioned between EtOAc and water. The organic phase was washed with water and brine, dried over Mg504, filtered and the solvent was removedvacuo. The product was purified by chromatography on silica eluting with iso-hexane/(EtOAc:MeOH - 10:1) to afford:Product Step 2a: tert- Butyl 4-(4-methyl-2 H- 1,2, 3-triazol-2-yl)piperidine- 1 -carboxylate;1H NMR (400 MHz, DMSO-d6) O 7.52 (iH, 5), 4.60 (iH, m), 3.93 (2H, m), 2.98 (2H, m), 2.21(3H, 5), 2.03 (2H, m), 1.80 (2H, m), 1.40 (9H, 5).Product Step 2b: tert- Butyl 4-(4-methyl- 1 H- 1,2, 3-triazol- 1 -yl)piperidine- 1 -carboxylate;1H NMR (400 MHz, DMSO-d6) O 7.91 (iH, 5), 4.62 (iH, m), 4.02 (2H, m), 2.92 (2H, m), 2.21(3H, 5), 2.01 (2H, m), 1.80 (2H, m), 1.42 (9H, 5).Product Step 2c: tert-Butyl 4-(5-methyl- 1 H- 1,2, 3-triazol- 1 -yl) piperidine- 1 -carboxylate;1H NMR (400 MHz, DMSO-d6) O 7.49 (1H, s), 4.51 (1H, m), 4.08 (2H, m), 2.97 (2H, m), 2.31(3H, s), 1.95 (2H, m), 1.87 (2H, m), 1.42 (9H, s).

Reference： [1]Patent: WO2015/8230,2015,A1 .Location in patent: Page/Page column 332

9
[ 22300-52-3 ]
[ 141699-59-4 ]
tert-butyl 4-(4-bromo-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate [ No CAS ]
tert-butyl 4-(4-bromo-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
33%; 20%		Step 2. tert-butyl 4-(4,5-dibromo-2H-l,2,3-triazol-2-yl)piperidine-l-carboxylate and tert-butyl 4-(4,5-dibromo-lH-l,2,3-triazol-l-yl)piperidine-l-carboxylate [0261] A mixture of 4,5-dibromo-2H-l,2,3-triazole (2.27 g, 10.08 mmol), tert-butyl 4- (methylsulfonyloxy)piperidine-l -carboxylate (2.79 g, 10.00 mmol), and cesium carbonate (9.75 g, 29.91 mmol) in N,N-dimethylformamide (50 mL) stirred overnight at 100 °C. The reaction mixture was cooled to room temperature, poured into water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to afford a mixture of tert-butyl 4-(4,5-dibromo-2H- 1 ,2,3- triazol-2-yl)piperidine- 1 -carboxylate and tert-butyl 4-(4,5-dibromo- 1 H- 1 ,2,3-triazol- 1 -yl)piperidine- 1-carboxylate (4.00 g, 97percent) as a yellow oil. MS (ESI, pos. ion) m/z 411 , 409, 413 [M+H]+. Step 3. tert-butyl 4-(4-bromo-2H-l,2,3-triazol-2-yl)piperidine-l-carboxylate (Intermediate 19) and tert-butyl 4-(4-bromo-lH-l,2,3-triazol-l-yl)piperidine-l-carboxylate (Intermediate 20) [0262] n-Butyllithium (2.5 M in hexanes, 2.92 mL, 7.30 mmol) was added dropwise to a -78 °C solution containing a mixture of tert-butyl 4-(4,5-dibromo-2H- 1,2, 3-triazol-2-yl)piperi dine- 1- carboxylate and tert-butyl 4-(4,5-dibromo-lH-l,2,3-triazol-l-yl)piperidine-l -carboxylate (3.00 g, 7.35 mmol) in tetrahydrofuran (20 mL). The resulting solution stirred for 1 hour at -78 °C, and then the reaction mixture was poured into saturated aqueous ammonium chloride solution (20 mL). The aqueous phase was separated and extracted with ethyl acetate (3 x 20 mL), and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified via column chromatography on silica gel (eluting with 2: 1, ethyl acetate/petroleum ether) to afford tert-butyl 4-(4-bromo-2H-l,2,3-triazol-2-yl)piperidine-l- carboxylate (0. 800 g, 33percent) as a colorless oil. MS (ESI, pos. ion) m/z 331, 333[M+H]+. [0263] tert-Butyl 4-(4-bromo-lH-l ,2,3-triazol-l-yl)piperidine-l-carboxylate (0.500g, 20percent) was also obtained as a colorless oil. MS (ESI, pos. ion) m/z 331, 333 [M+H]+.

Reference： [1]Patent: WO2015/74064,2015,A2 .Location in patent: Paragraph 0261-0263

10
[ 22300-52-3 ]
[ 141699-59-4 ]
tert-butyl 4-(4,5-dibromo-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate [ No CAS ]
tert-butyl 4-(4,5-dibromo-1H-1,2,3-triazol-1-yl)piperidine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With caesium carbonate; In N,N-dimethyl-formamide; at 100℃;	Step 2. tert-butyl 4-(4,5-dibromo-2H-l,2,3-triazol-2-yl)piperidine-l-carboxylate and tert-butyl 4-(4,5-dibromo-lH-l,2,3-triazol-l-yl)piperidine-l-carboxylate [0261] A mixture of 4,5-dibromo-2H-l,2,3-triazole (2.27 g, 10.08 mmol), tert-butyl 4- (methylsulfonyloxy)piperidine-l -carboxylate (2.79 g, 10.00 mmol), and cesium carbonate (9.75 g, 29.91 mmol) in N,N-dimethylformamide (50 mL) stirred overnight at 100 °C. The reaction mixture was cooled to room temperature, poured into water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to afford a mixture of tert-butyl 4-(4,5-dibromo-2H- 1 ,2,3- triazol-2-yl)piperidine- 1 -carboxylate and tert-butyl 4-(4,5-dibromo- 1 H- 1 ,2,3-triazol- 1 -yl)piperidine- 1-carboxylate (4.00 g, 97percent) as a yellow oil. MS (ESI, pos. ion) m/z 411 , 409, 413 [M+H]+.

Reference： [1]Patent: WO2015/74064,2015,A2 .Location in patent: Paragraph 0261

11
[ 5932-27-4 ]
[ 141699-59-4 ]
[ 782493-64-5 ]

Yield	Reaction Conditions	Operation in experiment
87%	With caesium carbonate; In N,N-dimethyl-formamide; at 5 - 90℃;	To a stirred solution of ethyl-I-H pyrazole carboxylate (5.0 g, 3.7mmol) in DMF (50 mL),Cs2CO3 (23 g, 71.3Smmol) and tert-butyl 4-((methylsulfonyl)-oxy) piperidine-I-carboxylate(9.9 g, 35.6 mmol) were added at 5 °C and reaction mixture was stirred at 90 °C overnight.The completion of the reaction was confirmed by TLC. The reaction mixture was pouredinto ice cold water. The resulting solid was filtered, washed with water (50 mL) and driedunder reduced pressure. It was used in the next step without any further purification. Yield:87percent (10 g, off white solid). 1H NMR (400 MHz, DMSO-d6 : 6 8.39 (5, IH), 7.87 (5, IH),4.45-4.39 (m, IH), 4.21 (q, J= 7.2 Hz, 2H), 4.05-4.02 (m, 2H), 2.01-1.98 (m, 2H), 1.85-1.78 (m, 2H), 1.42 (5, 9H), 1.26 (t, J = 7.2 Hz, 3H). LCMS: (Method A) 222.0 (M-Boc), Rt. 2.77 mm, 92.86percent (Max).

Reference： [1]Patent: WO2017/144633,2017,A1 .Location in patent: Page/Page column 105

12
[ 953410-86-1 ]
[ 141699-59-4 ]
tert-butyl 4-(5-bromo-7-iodo-2H-indazol-2-yl)piperidine-1-carboxylate [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2020,vol. 63,p. 8276 - 8295

Recommend Products

Same Skeleton Products

Related Products

Isomers

Technical Information

? Acyl Group Substitution ? Bouveault-Blanc Reduction ? Catalytic Hydrogenation ? Chan-Lam Coupling Reaction ? Complex Metal Hydride Reductions ? Ester Cleavage ? Halogenation ? Heat of Combustion ? Hydride Reductions ? Lawesson's Reagent ? Nucleophilicity of Sulfur Compounds ? Oxidation States of Sulfur Compounds ? Preparation of Amines ? Reactions of Amines ? Reactions with Organometallic Reagents ? Specialized Acylation Reagents-Carbodiimides and Related Reagents ? Specialized Acylation Reagents-Ketenes

Historical Records

Pharmaceutical Intermediates of
[ 141699-59-4 ]

Crizotinib Related Intermediates

[ 877397-70-1 ]

(R)-3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine

[ 877399-51-4 ]

(R)-tert-Butyl 4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate

[ 1207175-73-2 ]

tert-Butyl (5-bromo-3-hydroxypyridin-2-yl)carbamate

[ 756520-66-8 ]

1-(2,6-Dichloro-3-fluorophenyl)ethanol

[ 877399-00-3 ]

(R)-5-Bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine

Related Functional Groups of
[ 141699-59-4 ]

Amides

[ 129888-60-4 ]

tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.92

[ 404577-34-0 ]

(R)-1-N-Boc-3-Methanesulfonyloxypiperidine

Similarity: 0.92

[ 940890-90-4 ]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.92

[ 161975-39-9 ]

tert-Butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate

Similarity: 0.91

[ 141699-57-2 ]

tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.90

Sulfonates

[ 129888-60-4 ]

tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.92

[ 404577-34-0 ]

(R)-1-N-Boc-3-Methanesulfonyloxypiperidine

Similarity: 0.92

[ 940890-90-4 ]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.92

[ 161975-39-9 ]

tert-Butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate

Similarity: 0.91

[ 141699-57-2 ]

tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.90

Related Parent Nucleus of
[ 141699-59-4 ]

Aliphatic Heterocycles

[ 129888-60-4 ]

tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.92

[ 132945-75-6 ]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.90

[ 141699-57-2 ]

tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate

Similarity: 0.90

[ 109384-19-2 ]

tert-Butyl 4-hydroxypiperidine-1-carboxylate

Similarity: 0.70

[ 1179338-62-5 ]

tert-Butyl 4-(2-aminoethyl)-4-hydroxypiperidine-1-carboxylate

Similarity: 0.69

Piperidines

[ 129888-60-4 ]

tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.92

[ 404577-34-0 ]

(R)-1-N-Boc-3-Methanesulfonyloxypiperidine

Similarity: 0.92

[ 940890-90-4 ]

(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate

Similarity: 0.92

[ 161975-39-9 ]

tert-Butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate

Similarity: 0.91

[ 109384-19-2 ]

tert-Butyl 4-hydroxypiperidine-1-carboxylate

Similarity: 0.70

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

[ CAS No. 141699-59-4 ] {[proInfo.proName]}

Quality Control of [ 141699-59-4 ]

Related Doc. of [ 141699-59-4 ]

Product Details of [ 141699-59-4 ]

Calculated chemistry of [ 141699-59-4 ] Expand+

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 141699-59-4 ]

Application In Synthesis of [ 141699-59-4 ]

[ 141699-59-4 ] Synthesis Path-Upstream 1~2

[ 141699-59-4 ] Synthesis Path-Downstream 1~12

Technical Information

Pharmaceutical Intermediates of [ 141699-59-4 ]

Crizotinib Related Intermediates

Related Functional Groups of [ 141699-59-4 ]

Amides

Sulfonates

Related Parent Nucleus of [ 141699-59-4 ]

Aliphatic Heterocycles

Piperidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Pharmaceutical Intermediates of
[ 141699-59-4 ]

Related Functional Groups of
[ 141699-59-4 ]

Related Parent Nucleus of
[ 141699-59-4 ]